The preclinical reports do not resolve that balance for systemic dosing, and no human data address it
TB4 lowered oxidative stress and lipid peroxidation, boosted antioxidants, suppressed inflammation by inhibiting nuclear factor kappa B, and prevented liver fibrosis [38]
Retatrutide is currently the most powerful weight loss peptide in clinical development, producing 24.2% average weight loss over 48 weeks in Phase 2 trials
However, Tirzepatide has a unique advantage: it also activates GIP (Gastric Inhibitory Polypeptide) receptors, enhancing glycemic control by increasing insulin sensitivity and lipid (fat) metabolism
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA Copyright 2023, 2026, Eli Lilly and Company